| Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. | |
| | |
MedLine Citation:
|
PMID: 20381271 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Stereotactic body radiation therapy (SBRT) provides excellent local control with acceptable toxicity for patients with early-stage non-small cell lung cancer. However, the efficacy and safety of SBRT for patients previously given thoracic radiation therapy is not known. In this study, we retrospectively reviewed outcomes after SBRT for recurrent disease among patients previously given radiation therapy to the chest. MATERIALS AND METHODS: A search of medical records for patients treated with SBRT to the thorax after prior fractionated radiation therapy to the chest at The University of Texas M. D. Anderson Cancer Center revealed 36 such cases. The median follow-up time after SBRT was 15 months. The endpoints analyzed were overall survival, local control, and the incidence and severity of treatment-related toxicity. RESULTS: SBRT provided in-field local control for 92% of patients; at 2 years, the actuarial overall survival rate was 59%, and the actuarial progression-free survival rate was 26%, with the primary site of failure being intrathoracic relapse. Fifty percent of patients experienced worsening of dyspnea after SBRT, with 19% requiring oxygen supplementation; 30% of patients experienced chest wall pain and 8% Grade 3 esophagitis. No Grade 4 or 5 toxic effects were noted. CONCLUSIONS: SBRT can provide excellent in-field tumor control in patients who have received prior radiation therapy. Toxicity was significant but manageable. The high rate of intrathoracic failure indicates the need for further study to identify patients who would derive the most benefit from SBRT for this purpose. |
| | |
Authors:
|
Patrick Kelly; Peter A Balter; Neal Rebueno; Hadley J Sharp; Zhongxing Liao; Ritsuko Komaki; Joe Y Chang |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-04-08 |
Journal Detail:
|
Title: International journal of radiation oncology, biology, physics Volume: 78 ISSN: 1879-355X ISO Abbreviation: Int. J. Radiat. Oncol. Biol. Phys. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2010-12-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7603616 Medline TA: Int J Radiat Oncol Biol Phys Country: United States |
Other Details:
|
Languages: eng Pagination: 1387-93 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung / mortality, pathology, radiotherapy, surgery* Disease-Free Survival Dose Fractionation Female Humans Lung Neoplasms / mortality, pathology, radiotherapy, surgery* Male Middle Aged Neoplasm Recurrence, Local / mortality, pathology, surgery* Neoplasm Staging Radiosurgery / adverse effects, methods*, mortality Retrospective Studies Survival Rate Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
P50 CA70907/CA/NCI NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Results of a multi-institutional benchmark test for cranial CT/MR image registration.
Next Document: Impact of maternal age distribution on the expected live birth prevalence of Down's syndrome in the ...